Directed walk designs for dose-response problems with competing failure modes

DOI10.1111/1541-0420.00029MaRDI QIDQ3079102zbMATH OpenOpenAlexWikidataFDO

Authors Mary C. Meyer, Q. F. Stout, Janis P. Hardwick

Publication date 1 March 2011

Published in Biometrics (Search for Journal in Brave)

Full work available at URL http://hdl.handle.net/2027.42/66162

zbMATH Keywords

Bayesianconvex-concaveCRMefficiencyexperimental designisotonicnonparametricphase I/IIrandom walksequentialunimodal

Mathematics Subject Classification ID

Optimal statistical designs (62K05) Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)

Recommendations

• A Random Walk Rule for Phase I Clinical Trials
• Up-and-down designs for dose-finding
• Up-and-Down Designs for Selecting the Dose with Maximum Success Probability
• An optimizing up-and-down design
• Optimal adaptive designs for binary response trials

Cites work

• A comparison of nonparametric shape constrained bioassey estimators
• A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Designs for Phase II Trials Allowing for a Trade-Off between Response and Toxicity
• Dose-finding designs for HIV studies
• Group Sequential Tests for Bivariate Response: Interim Analyses of Clinical Trials with Both Efficacy and Safety Endpoints
• Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials
• Predictive Variable Selection in Generalized Linear Models

Cited in

(7)

• Weighted \(L_{\infty}\) isotonic regression
• Adaptive designs for dose-finding based on efficacy-toxicity response
• A Random Walk Rule for Phase I Clinical Trials
• Optimizing a unimodal response function for binary variables
• Up-and-Down Designs for Selecting the Dose with Maximum Success Probability
• Combined criteria for dose optimisation in early phase clinical trials
• Defining utility as a measure of preference under uncertainty in phase I-II oncology dose finding trials

This page was built for publication: Directed walk designs for dose-response problems with competing failure modes

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3079102)